Data and Analysis

Will AI drive a revolution in drug discovery? Ben Hirschler examines how it is being used to sift through a mountain of health-related data—including his own biomedical records.

After decades of neglect, it’s time to recognize that investing in women’s health is the right and smart thing to do. Ben Hirschler and Charis Gresser report.

ESG analysis is establishing itself as core business practice despite entrenched efforts to dismiss it, say Brunswick’s Dan Lambeth & Kanhai Parasharya.

Yes—but maybe not. It’s complicated. Scott Foster reports.

Moody’s CEO Rob Fauber says that we’re living in a new era of risk. By Brunswick’s Craig Mullaney and Bill Pendergast.

Brunswick Insight’s Zayd Mabruk reports.

Satellite-based tracking of CO2 and methane emissions represent the dawn of a new era for business transparency, says Antoine Rostand, CEO of tracking platform Kayrros.

Brunswick Insight’s poll of employees reveals how they would like their companies to respond. By Mara Riemer.

New Brunswick research on what the public took away from the historic climate conference.

Retail investors now own roughly 14% of the S&P 500—up from 11% two years ago. With a surge of new shareholders, recent research from Brunswick shows how companies can connect with their evolving ownership base.

The pharmaceutical industry is seizing the moment to both help lift society out of the pandemic and rebuild its own reputation. The clock is ticking. By Brunswick’s Ben Hirschler and Jeremy Ruch.